



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: September 8, 2006

To: Primary Clinical Research Associates

From: Janis Wobschall
Protocol Development Coordinator

Re: N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

Attached, please find a revised status change notice dated August 4, 2006 which now correctly reflects that this study is **temporarily** closed rather than permanently closed.

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg
Enclosure

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Revised Status Change – August 4, 2006

NOTICE OF STATUS CHANGE

This study reopened to patient accrual effective Friday, August 4, 2006 due to the late identification of 1 unevaluable patient. Another patient was immediately identified and the study **temporarily** closed to patient accrual the same day it was reopened, Friday, August 4, 2006.

Please retain this notice with the protocol.